biontech
Pfizer and BioNTech will start a clinical trial for an Omicron-specific vaccine. The study will include three cohorts of healthy adult participants ranging from ages 18 to 55. The first group will include those who had two doses of the Pfizer vaccine at least 90 to 180 days ahead of the study. They will receive either one or two doses of the Omicron vaccine. The second group will be made of participants who have had three doses of the Pfizer vaccine, also at least 90-180 days prior. This group will be given one dose of the Omicron-specific vaccine. Finally, the third group will include partici...
uPolitics.com
Vaccine manufacturers Pfizer and BioNTech have announced that two doses of their Covid-19 vaccine provide significant protection against the rapidly spreading omicron variant and that a supplemental booster shot was found to “neutralize” the mutated pathogen, based on blood tests that they conducted from individuals who had received second and third injections. “Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers,” the pharmaceutica...
uPolitics.com
Pfizer CEO Albert Bourla said that recipients of his company’s COVID-19 vaccination, as well as those of similar make-up like the Moderna vaccine, will “likely” require a third dose for increased immunity against the virus and its variants. Bourla also indicated people may need annual doses of the vaccine, similar to a flu shot. “A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual re-vaccination, but all of that needs to be confirmed. And again, the variants will play a key role,” Bourla said i...
uPolitics.com
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら